Form 4: Nuvalent Director Michael L. Meyers Reports Acquisition of Shares and Stock Options

Director Michael L. Meyers reports acquisition of Nuvalent, Inc. Class A Common Stock and stock options.

Summary

• On June 12, 2024, Michael L. Meyers, a director of Nuvalent, Inc., acquired 2,499 shares of Class A Common Stock under restricted stock units (RSUs) at a price of $0.00 per share.
• These RSUs vest in full on the earlier of June 12, 2025, or the date of Nuvalent, Inc.'s next annual meeting of stockholders, contingent upon continued service to the company.
• Additionally, Meyers acquired stock options for 3,789 shares of Class A Common Stock with an exercise price of $80.03 per share.
• These options also vest in full on the earlier of June 12, 2025, or the date of Nuvalent, Inc.'s next annual meeting of stockholders, subject to continued service.
• Following these transactions, Meyers directly owns 2,499 shares of Class A Common Stock and holds options for 3,789 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The acquisition of shares and options by a director suggests confidence in the company's prospects, but it's a routine transaction.

Positives

• The acquisition of shares and stock options by a director signals confidence in the company's future prospects.
• The vesting schedules tied to continued service align the director's interests with the long-term success of Nuvalent, Inc.

Future Outlook

The vesting schedules for the RSUs and stock options indicate a commitment to the company's future, with vesting contingent on continued service through the earlier of June 12, 2025, or the next annual meeting.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency regarding the transactions of company insiders, such as directors and officers, in the company's securities. This filing indicates a director's increased stake in the company, which is generally viewed positively by investors.

Comparison to Industry Standards

• Stock option grants and RSU awards are common forms of compensation for directors and executives in publicly traded companies, particularly in the biotechnology and pharmaceutical industries.
• The vesting schedules, typically tied to continued service, are standard practice to align the interests of management with those of shareholders.
• The specific terms of the grants, such as the exercise price and vesting dates, are comparable to those offered by similar companies to their directors.

Stakeholder Impact

• Shareholders may view the director's increased stake in the company positively.
• Employees may see this as a sign of confidence in the company's future.

Key Dates